A total of 52 patients were enrolled and treated with the efgartigimod (n=16), IVIg (n=20), or efgartigimod plus IVIg (n=16). At week 4, the proportion of patients reaching GBS-DS ≤1 was numerically superior in the efgartigimod group (62.5%) compared to the IVIg (45.0%) and combination (37.5%) groups, although the difference was not statistically significant (p=0.35). In addition, the time for efgartigimod group to reach GBS≤1 was 2.6±1.17weeks, compared to the 3.11±1.05 and 2.83±1.17weeks in other two group, efgartigimod seemed to help patients achieve good functional prognosis faster, but also did not reach statistical differences(p=0.62). A lower incidence of treatment-related adverse events (TEAEs)was observed in the efgartigimod group (18.8%, 3/16) compared to the IVIg (50.0%, 10/20) and combination (43.8%, 7/16) groups.